The second clinic in Sweden has now successfully treated the first patients with benign prostatic enlargement using the new CoreTherm® Eagle, further expanding the adoption of our new platform.
“We are excited to see our second clinic in Sweden now up and running with CoreTherm® Eagle. The successful treatments of the first patients mark yet another important milestone in our continued rollout. Next step is to implement CoreTherm® Eagle at one of our Centers of Excellence in Denmark. Following this, we plan to expand the launch beyond the Nordic region, bringing the benefits of CoreTherm® Eagle to a broader international market,” says Malin Melander, acting CEO and COO at ProstaLund.
CoreTherm® Eagle builds on the proven and well-established technology that has been developed and refined over 25 years in earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia in the Nordics. The new CoreTherm® Eagle has undergone significant technical and component upgrades. Among other things, the calculation of recommended treatment goals has been automated and integrated into the new platform. This provides increased support for the user and further enhances ease of use.